Search research articles
Contact Us
Filters
Showing results (91-100 of 124) with videos related to
Page
of 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 1998
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer
A Giatromanolaki, M I Koukourakis, S Kakolyris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2002
Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance
A Stathopoulou, I Vlachonikolis, D Mavroudis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer
C Kouroussis, N Androulakis, S Kakolyris, et al.
Anticancer Research
|
May 1, 1997
p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1
E Giannikaki, C Kouvidou, M Tzardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2003
Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer
N Xenidis, I Vlachonikolis, D Mavroudis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2000
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study
T Giannakakis, N Ziras, S Kakolyris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2001
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer
D Mavroudis, E Papadakis, M Veslemes, et al.
British Journal of Cancer
|
January 14, 2012
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
J Souglakos, N Ziras, S Kakolyris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2009
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
D Mavroudis, P Papakotoulas, A Ardavanis, et al.
Anticancer Research
|
August 15, 1998
Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue
K Stefanaki, M Tzardi, C Kouvidou, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 124) with videos related to
Sort By:
Page
of 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 29, 1998
Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer
A Giatromanolaki, M I Koukourakis, S Kakolyris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2002
Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance
A Stathopoulou, I Vlachonikolis, D Mavroudis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 1999
Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer
C Kouroussis, N Androulakis, S Kakolyris, et al.
Anticancer Research
|
May 1, 1997
p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1
E Giannikaki, C Kouvidou, M Tzardi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 11, 2003
Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer
N Xenidis, I Vlachonikolis, D Mavroudis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 14, 2000
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study
T Giannakakis, N Ziras, S Kakolyris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2001
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer
D Mavroudis, E Papadakis, M Veslemes, et al.
British Journal of Cancer
|
January 14, 2012
Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC)
J Souglakos, N Ziras, S Kakolyris, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2009
Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer
D Mavroudis, P Papakotoulas, A Ardavanis, et al.
Anticancer Research
|
August 15, 1998
Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue
K Stefanaki, M Tzardi, C Kouvidou, et al.
Page
of 13